Zacks Investment Research
09 Sept 2026, 22:50 UTC · 1w ago
Verdict
Headline takes no side. We score VKTX −0.40 across four claims — moderately bearish.
−0.40moderately bearish
More negative than 77% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Viking Therapeutics (VKTX) is expected to report quarterly EPS of -$1, a 23.46% decrease from the prior-year quarter.
So whatA significant decline in earnings per share compared to the previous year typically pressures stock prices.
More negative than 87% of claims this week
The Zacks Consensus EPS estimate for Viking Therapeutics has shifted 0.71% upward over the past month.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More positive than 49% of claims this week
The Medical - Biomedical and Genetics industry is ranked in the bottom 35% of all industries monitored by Zacks.
More negative than 72% of claims this week
Viking Therapeutics currently carries a Zacks Rank of #3 (Hold).
Near neutral — 99% of claims this week are stronger
Which stocks this story touches
More negative than 77% of ticker scores this week
The company experienced a recent price drop, is underperforming its sector, and is expecting a significant decrease in EPS.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
+22.7%
Price is moving against the score
$40.12 vs $32.70 close before publication (Sep 9) · not market-adjusted
VKTX chart →